摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-phenyl)-propan-1-one | 277313-10-7

中文名称
——
中文别名
——
英文名称
1-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-phenyl)-propan-1-one
英文别名
1-(3-bromo-2-hydroxy-5-methylphenyl)-3-(4-nitrophenyl)propan-1-one
1-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-phenyl)-propan-1-one化学式
CAS
277313-10-7
化学式
C16H14BrNO4
mdl
——
分子量
364.195
InChiKey
QCKHUFGDYYSTDQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    83.1
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    1-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-phenyl)-propan-1-one4-hydrazino-benzamidineN,N-二异丙基乙胺 作用下, 以 乙醇 为溶剂, 反应 4.0h, 以90%的产率得到4-{N'-[1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-phenyl)-propylidene]-hydrazino}-benzamidine
    参考文献:
    名称:
    (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
    摘要:
    本发明提供了Formula (I)的新化合物:A-B,其前药形式,或其药学上可接受的盐,其中A代表饱和、不饱和或部分不饱和的双环杂环环结构,B代表芳基或杂芳基团。本发明的首选化合物包括苯并咪唑或吲哚核。本发明的化合物是丝氨酸蛋白酶、尿激酶(uPA)、Xa因子(FXa)和/或VIIa因子(FVIIa)的抑制剂,并具有作为抗癌剂和/或抗凝血剂的用途,用于治疗或预防哺乳动物的血栓栓塞疾病。
    公开号:
    US06867200B1
点击查看最新优质反应信息

文献信息

  • (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS
    申请人:AXYS PHARMACEUTICALS, INC.
    公开号:EP1140859A2
    公开(公告)日:2001-10-10
  • US6867200B1
    申请人:——
    公开号:US6867200B1
    公开(公告)日:2005-03-15
  • [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
    申请人:AXYS PHARM INC
    公开号:WO2000035886A2
    公开(公告)日:2000-06-22
    The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
  • (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
    申请人:Allen Darin A.
    公开号:US06867200B1
    公开(公告)日:2005-03-15
    The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
    本发明提供了Formula (I)的新化合物:A-B,其前药形式,或其药学上可接受的盐,其中A代表饱和、不饱和或部分不饱和的双环杂环环结构,B代表芳基或杂芳基团。本发明的首选化合物包括苯并咪唑或吲哚核。本发明的化合物是丝氨酸蛋白酶、尿激酶(uPA)、Xa因子(FXa)和/或VIIa因子(FVIIa)的抑制剂,并具有作为抗癌剂和/或抗凝血剂的用途,用于治疗或预防哺乳动物的血栓栓塞疾病。
查看更多